Roche ($RHHBY) has stepped up with a $392 million deal designed to marry its work on new technology for delivering brain treatments with Isis' ($ISIS) antisense programs for Huntington's disease. In the deal, the latest in a lengthy string for the Carlsbad, CA-based biotech company, Isis gains $30 million upfront with the rest payable on promised milestones. Report